The plans include the acquisition of more than 170 million doses of the new boosters, which will be available to consumers without an out-of-pocket cost.
U.S. health regulators last month authorized injecting the shot intradermally in adults, meaning between layers of the skin rather than below the skin, in an effort to stretch out low vaccine supplies. read more
WASHINGTON — Researchers studying next-generation vaccines to fight an evolving Covid-19 threat are running into problems getting existing vaccines to use in their research.
These mucosal vaccines target thin mucous membranes that line the nose, mouth and lungs. By prompting immune responses where SARS-CoV-2 first enters the body, mucosal vaccines could, in theory, prevent even mild cases of illness and block transmission to other people — something COVID-19 shots have been unable to do. Vaccines that produce sterilizing immunity would be game changing for the pandemic. ...
The antibody reported as having been isolated at the IIBR is monoclonal, meaning it was derived from a single recovered cell and is thus potentially of more potent value in yielding a treatment.
The additional doses will be available for delivery before the end of the year, while shots that were purchased earlier are currently being distributed, the EU Commission said.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/53IDYKW3PJI4VOZSHM4ADOSXDA.jpg)
